poa/neoplasms

Recently, there has been an increasing interest in the diagnostic and prognostic usefulness of tumor-associated antigen of embryonic and fetal origin. Many approaches have been attempted to make an early diagnosis of the pancreatic cancer, where a specific screening blood test for the pancreatic

Pancreatic oncofetal antigen (POA) was purified from fetal pancreas and migrated in beta-region electrophoretically. Its molecular weight was 80 X 10(4) daltons. Enzyme immunoassay for serum POA revealed that elevated levels of POA were found in sera of patients with pancreatic cancer. By a

Pancreatic oncofetal antigen (POA) is considered to be an oncofetal antigen for human pancreas, and its measurement seems to be useful in the diagnosis of pancreatic cancer. In this study, POA, CEA, ferritin, BMG (beta 2 microglobulin) and AFP either in sera in pancreatic juice were measured in

Pancreatic oncofetal antigen (POA) was detected in the pure pancreatic juice by double immunodiffusion assay in a series of patients, using anti-POA prepared by immunizing rabbits with human fetal pancreas homogenate. The test was positive in as many as 72% of the patients with pancreatic cancer

We investigated the usefulness of enzyme immunoassay (EIA) for pancreatic oncofetal antigen (POA). The crude POA isolated from POA-positive ascitic fluid of patients with pancreatic cancer was injected into rabbits to raise anti-POA serum. The adsorbed antiserum was used for EIA as anti-POA serum.

Our studies on the partial purification, characterization and clinical application of pancreatic oncofetal antigen (POA) are presented. This antigen was purified from fetal pancreas and migrated in beta-region electrophoretically. Its molecular weight was estimated approximately 80 X 10(4) daltons

With respect to their diagnostic utility CA 19-9, CEA, AFP and POA were determined in pancreatic secretions and serum of patients suffering from pancreatic cancer (n = 76/55) or chronic pancreatitis (n = 79/45) and of controls (n = 81/42), respectively. While the determination of AFP and POA both in

Gliomas are the most frequent primary tumours of the nervous system, characterised by high degree of malignancy, widespread invasion and high-rate proliferation. Cisplatin and analogue are currently employed in clinical trials as active chemotherapeutic agents for the systemic treatment of this type

Serum levels of POA (EIA; less than 11.0 U/ml) and CA 19-9 (RIA; less than or equal to 37 U/ml) were measured in 54 patients with pancreatic cancer and 19 patients with benign diseases of the pancreas. Although serum CA 19-9 and POA were elevated in 72.7% and 69.4% of patients with pancreatic

Pancreatic oncofetal antigen (POA) was measured by enzyme immunoassay in pancreatic juice from patients with pancreatic cancer, chronic pancreatitis, or other diseases. POA levels in pancreatic cancer were significantly higher than in other disorders, and POA was seen by immunofluorescence to be in

A hamster serum protein which reacted with anti-human pancreatic oncofetal antigen (POA) was identified in sera from hamsters with varying types of pancreatic pathology. Hamsters were treated with N-nitrobis-(2-hydroxypropyl)-amine, and histological findings in the pancreas were correlated with

This study examined the role of purpose of admission (POA) in hospitalizations for lung, colon, and breast cancers, using the 1985 20-percent Medicare provider analysis and review file. Six POA categories were created from discharge abstract data. Average hospitalization charges, per diem charges,